Finding studies
Finding studies
Take this into the appointment.
Saves the questions and what to expect into your notes, next to the visit they belong to.
Lead
City of Hope Medical Center
With
PRIMARY OBJECTIVE: I. Obtain a preliminary estimate of the safety and tolerability of the combination of cosibelimab with lenalidomide in patients with relapsed/refractory (R/R) mycosis fungoides (MF) or Sézary Syndrome (SS). SECONDARY OBJECTIVE: I. Obtain a preliminary estimate of the efficacy of the combination of cosibelimab with lenalidomide in patients with relapsed/refractory (R/R) mycosis fungoides (MF) or Sézary Syndrome (SS), as assessed by overall response rate (ORR), complete response (CR) rate, time to response, duration of response, sustained response (ORR4), progression-free survival, and overall survival. EXPLORATORY OBJECTIVES: I. To obtain a preliminary assessment of quality of life (QoL) parameters before, during and after the regimen. II. To evaluate the anti-tumor and immunomodulatory effects in the tumor microenvironment in skin and blood samples of patients with R/R MF or SS treated with combination cosibelimab and lenalidomide. OUTLINE: This is a dose-escalation study of lenalidomide in combination with fixed dose cosibelimab followed by a dose-expansion study. Patients receive cosibelimab intravenously (IV) over 1 hour on day 1 and lenalidomide orally (PO) once daily (QD) on days 1-14 of each cycle. Cycles repeat every 21 days for up to 18 cycles in the absence of disease progression or unacceptable toxicity. Patients undergo computed tomography (CT) scan with or without positron emission tomography (PET) at baseline and may undergo CT scan with or without PET scan throughout the trial. Patients undergo skin biopsy and blood sample collection throughout the study. After completion of study treatment, patients are followed up at 30, 60, and 90 days then every 2 months until progression or initiation of a new therapy (for patients without progression) or every 6 months for patients in survival follow up.
Age
18–any
Sex
ALL
Healthy volunteers
Not accepted
